CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Replimune Group, Inc.

REPL
$523M
Small Cap
NASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaWOBURN479 employees

Drugs in Pipeline

7

Phase 3 Programs

2

Upcoming Catalysts

5

Next Catalyst

Apr 1, 2026

7w
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

5 upcoming, 1 past

🎯PDUFANext

FDA PDUFA Date RP1 (priority)

4/1/2026

For solid tumors. BLA filing. Extracted from SEC filing: 8-K

Source
🎯PDUFA

FDA PDUFA Date

6/3/2026

Extracted from SEC filing: 8-K

Source
🎯PDUFA

FDA PDUFA Date lifileucel (priority)

6/19/2026

For advanced melanoma. BLA filing. Extracted from SEC filing: 8-K

Source
Phase 2

RP3 Phase 2 Results Expected

Jan 1, 2027RP34

Primary completion for RP3 trial (NCT05733611) in Refractory Metastatic Colorectal Cancer

Source
Phase 2

RP2 Phase 2 Results Expected

Jan 1, 2027RP24

Primary completion for RP2 trial (NCT05733611) in Refractory Metastatic Colorectal Cancer

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Vusolimogene Oderparepvec

Phase 3

Advanced Melanoma

RP2

Phase 3

Metastatic Uveal Melanoma

RP1

Phase 2

Non-Small Cell Lung Cancer (NSCLC)

RP3

Phase 2

Refractory Metastatic Colorectal Cancer

Cemiplimab

Phase 2

Cutaneous Squamous Cell Carcinoma

RP1, intra-tumoral injection, oncolytic virus

Phase 2

Cutaneous Squamous Cell Carcinoma

RP2 Monotherapy

Phase 2

Hepatocellular Carcinoma

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals
REPL News